ABSTRACT
This chapter aims to review many of the current minimally invasive techniques for the treatment of benign prostatic hyperplasia (BPH) and evaluate their success, morbidities, and mortalities compared to transurethral resection of the prostate (TURP). Azotemia may also contribute to preoperative risk, and as such, preoperative bladder drainage should be performed to relieve urinary retention secondary to outlet obstruction, especially if upper tract damage has occurred. Transurethral electrovaporization of the prostate (TUEVP) is a modification of existing transurethral technology and has been viewed as one of the most promising alternatives to TURP. Transurethral resection of the prostate is currently considered to be the gold standard treatment for patients with BPH, the most common benign tumor in elderly men. However, while the efficacy and durability of TURP have been proved time and again, so have the associated morbidities.
